EGFR and neoplasm: We hypothesized that CTCs and inflammatory markers (using NLR and dNLR) are surrogates of response to EGFR-targeted therapy that may be used as biomarkers and complement the use of circulating tumor DNA (ctDNA) in the diagnosis and prognosis of NSCLC patients.